CD138/syndecan-1: A useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies

Modern Pathology

Volumn 12, Issue 12, 1999, Pages 1101-1106

  Chilosi, Marco ^a   Adami, Fausto ^b   Lestani, Maurizio ^b   Montagna, Licia ^b   Cimarosto, Lorella ^b   Semenzato, Gianpietro ^b   Pizzolo, Giovanni ^b   Menestrina, Fabio ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b NONE

Author keywords

CD138; Immunohistochemistry; Lymphoma; Myeloma; Plasma cells

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BB 4; PROTEIN P53; SYNDECAN; SYNDECAN 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW BIOPSY; CONTROLLED STUDY; DIAGNOSTIC VALUE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS;

BIOPSY; BONE MARROW NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LEUKEMIA, LYMPHOCYTIC; LYMPHOMA, B-CELL; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; PLASMA CELLS; PROTEOGLYCANS; SYNDECAN-1; SYNDECANS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033391911     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Bartl R, Frisch B, Fateh-Moghadam A, Kettner G, Jaeger K, Sommerfeld W. Histologic classification and staging of multiple myeloma: a retrospective and prospective study of 674 cases. Am J Clin Pathol 1987;87:342-55.
2. Canale DD, Collins RD. Use of bone marrow particle sections in the diagnosis of multiple myeloma. Am J Clin Pathol 1974;61:382-92.
3. Kyle RA. Diagnostic criteria of multiple myeloma. Hematol Oncol Clin North Am 1992;6:347-58.
4. Pinkus GS, Said JW. Specific identification of intracellular immunoglobulin in paraffin sections of multiple myeloma and macroglobulinemia using an immunoperoxidase technique. Am J Pathol 1977;87:47-58.
5. Thiele J, Arenz B, Klein H, Vierbuchen M, Zankovich R, Fischer R. Differentiation of plasma cell infiltrates in the bone marrow: a clinicopathological study on 80 patients including immunohistochemistry and morphometry. Virchows Arch Pathol Anat 1988;412:553-62.
6. Wolf BC, Brady K, O'Murchadha MT, Neiman RS. An evaluation of immunohistologic stains for immunoglobulin light chains in bone marrow biopsies in benign and malignant plasma cell proliferations. Am J Clin Pathol 1990;94:742-6.
7. Thiry A, Delvenne P, Fontaine MA, Boniver J. Comparison of bone marrow sections, smears and immunohistological staining for immunoglobulin light chains in the diagnosis of benign and malignant plasma cell proliferations. Histopathology 1993;22:423-8.
8. Sukpanichnant S, Cousar JB, Leelasiri A, Graber SE, Greer JP, Collins RD. Diagnostic criteria and histologic grading in multiple myeloma: histologic and immunohistologic analysis of 176 cases with clinical correlation. Hum Pathol 1994; 25:308-18.
9. Anderson KC, Park EK, Bates MP, Leonard RC, Hardy R, Schlossman SF, et al. Antigens on human plasma cells identified by monoclonal antibodies. J Imnumol 1983;130:1132-8.
10. Tong AW, Lee JC, Stone MJ. Characterization of a monoclonal antibody having selective reactivity with normal and neoplastic plasma cells. Blood 1987;69:238-45.
11. Turley H, Jones M, Erber W, Mayne K, de Waele M, Gatter K. VS38: a new monoclonal antibody for detecting plasma cell differentiation in routine sections. J Clin Pathol 1994;47:418-22.
12. Vallario A, Chilosi M, Adami F, Montagna L, Deaglio S, Malavasi F, et al. Human myeloma cells express the CD38 ligand CD31. Br J Haematol 1999;105:441-4.
13. Mullink H, Henzen-Logmans SC, Tadema TM, Mol JJ, Meijer CJLM. Influence of fixation and decalcification on the immunohistochemical staining of cell-specific markers in paraffin embedded human bone biopsies. J Histochem Cytochem 1985;33:1103-9.
14. Taylor CR, Russel R, Chandor S. An immunohistologic study of multiple myeloma and related conditions, using an immunoperoxidase method. Am J Clin Pathol 1978;70:612-22.
15. Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL, et al. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Ann Rev Cell Biol 1992; 8:365-93.
16. Carey DJ. Syndecans: multifunctional cell-surface co-receptors. Biochem J 1997;327:1-16.
17. Kato M, Wang H, Kainulainen V, Fitzgerald ML, Ledbetter S, Ornitz DM, et al. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med 1998;4:691-7.
18. Ridley RC, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson RD. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood 1993;81:767-74.
19. Sanderson RD, Sneed TB, Young LA, Sullivan GL, Lander AD. Adhesion of B lymphoid (MPC-II) cells to type I collagen is mediated by the integral membrane proteoglycan syndecan. J Immunol 1992;148:3902.
20. Liebersbach BF, Sanderson RD. Expression of syndecan-1 inhibits cell invasion into type I collagen. J Biol Chem 1994; 269:20013-9.
21. Dhodapkar MV, Abe E, Theus A, Lacy M, Langford JK, Barlogie B, et al. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood 1998;91:2679-88.
22. Wijdenes J, Vooijs WC, Clement C, Post J, Morard F, Vita N, et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 1996;94:318-23.
23. Sun RX, Lu ZY, Wijdenes J, Brochier J, Hertog C, Rossi JF, et al. Large scale and clinical grade purification of syndecan-1+ malignant plasma cells. J Immunol Methods 1997;205:73-9.
24. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361.
25. Chilosi M, Doglioni C, Menestrina F, Montagna L, Rigo A, Lestani M, et al. Abnormal expression of the p53-binding protein mdm2 in Hodgkin's disease. Blood 1994;84:4295-300.
26. Peterson LC, Brown BA, Crosson JT, Mladenovic J. Application of the immunoperoxidase technique to bone marrow trephine biopsies in the classification with monoclonal gammopathies. Am J Clin Pathol 1986;85:688-93.
27. Inki P, Jalkanen M. The role of syndecan-1 in malignancies. Ann Med 1996;28:63-7.
28. Banham AH, Turley H, Pulford K, Gatter K, Mason DY. The plasma cell associated antigen detectable by antibody VS38 is the p63 rough endoplasmic reticulum protein. J Clin Pathol 1997;50:485-9.
29. Strand WR, Banks PM, Kyle RA. Anaplastic plasma cell myeloma and immunoblastic lymphoma: clinical, pathologic, and immunologic comparison. Am J Med 1984;76:861-7.
30. Strickler JG, Audeh W, Copenhaver CM, Warnke RA. Immunophenotypic differences between plasmacytoma/multiple myeloma and immunoblastic lymphoma. Cancer 1988;61: 1782-6.
31. Gaidano G, Gloghini A, Gattei V, Rossi MF, Cilia AM, Godeas C, et al. Association of Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138/syndecan-1 antigen. Blood 1997;90: 4894-900.
32. Sebestyen A, Kovalszky I, Mihalik R, Gallai M, Bocsi J, Laszlo E, et al. Expression of syndecan-1 in human B cell chronic lymphocytic leukaemia. Eur J Cancer 1997;33:2273-7.
33. Durie BG, Salmon SE, Moon TE. Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood 1980;55:364-72.
34. Boccadoro M, Massaia M, Dianzani U, Pileri A. Multiple myeloma: biological and clinical significance of bone marrow plasma cell labeling index. Haematologica 1987;72:171-5.
35. Boccadoro M, Gavarotti P, Fossati G, Pileri A, Marmont F, Neretto G, et al. Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy. Br J Haematol 1984;58:689-96.
36. Lockhorst HM, Boom SE, Terpstra W, Roholl P, Gerdes J, Bast BJ. Determination of the growth fraction in monoclonal gammopathy with the monoclonal antibody Ki-67. Br J Haematol 1988;69:477-81.
37. Pich A, Chiusa L, Marmont F, Navone R. Risk groups of myeloma patients by histologic pattern and proliferative activity. Am J Surg Pathol 1997;21:339-47.